Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Biomedical Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9434 Online ISSN: 2049-9442
Journal Cover
July-August 2013 Volume 1 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-August 2013 Volume 1 Issue 4

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time

  • Authors:
    • Hyeong‑U Son
    • Sang‑Han Lee
  • View Affiliations / Copyright

    Affiliations: Department of Food Science and Biotechnology, Kyungpook National University, Daegu 702‑701, Republic of Korea
  • Pages: 624-628
    |
    Published online on: May 22, 2013
       https://doi.org/10.3892/br.2013.111
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Cudrania tricuspidata (CT) is a type of add‑value beneficial plant. The aim of the present study was to determine the components of CT that inhibit α‑glucosidase activity. roots, leaves and stems of the plants were obtained and several subgroups were created according to harvesting time. Root extracts exhibited a 77% velocity inhibition at a concentration of 300 µg/ml and an inhibitory constant of 41.6 µg/ml. The inhibitory percentage of the positive control at 1 mM was ~67% of the enzymatic velocity with acarbose. According to the Michaelis‑Menten equation, the type of inhibitory mechanism underlying the effects of the stem and root samples according to climate was competitive or non‑competitive inhibition, suggesting that the extracts contain additional antidiabetic compounds produced during the growth period. Collectively, the results from our study suggested that stem and root extracts of CT serve as an antidiabetic biomaterial and contain a variety of antidiabetic compounds.

Introduction

Following food ingestion, carbohydrates are converted into glucose by several enzymes. Among these, α-glucosidase is produced by intestinal cells or tissues and cleaves glycosidic bonds in oligosaccharides during the last step of hydrolysis (1). Glucose is the main component of blood sugar. Therefore, α-glucosidase may be an ideal target for the treatment of type 2 diabetes mellitus (2). To investigate antidiabetic properties for nutraceutical purposes, this enzyme may also be used as a marker for in vitro assays, since the α-glucosidase inhibitor induces hypoglycemic symptoms less frequently compared to other oral glucose-lowering agents (3).

Cudrania tricuspidata (CT) belongs to the Moraceae family and is distributed throughout Korea, Japan and China (4). Ethanol extracts of CT contain numerous compounds, including butyrospermyl acetate, glutinol, taraxerone, quercetin, kaempferol, isorhamnetin, orobol, 3′-O-methyorobol, 1,3,6,7-tetrahydroxyxanthone, taxifolin, naringenin, steppogenin and 5,7-dihydroxy chromone (5). Various effects of CT, such as tyrosinase inhibition (6), anti-oxidative activity (7) and anti-inflammatory activity (8) have been investigated. Its active ingredients have also been isolated and they include prenylated xanthones (mainly cudraxanthone) and cudraflavone (9). Although isolated CT compounds have already been proven to possess anti-diabetic properties using α-glucosidase inhibitory assays (2), studies on the potential activity of CT from various sources have not yet been performed.

Recently, the consumption of crude CT extract in Korea was abruptly increased due to its potential benefits as a traditional complementary therapy. However, information regarding the functional activities of different plant components according to harvesting time has not yet been obtained. Therefore, additional studies are required to optimize the commercial preparation of CT extracts. In the present study, CT samples were divided according to plant component and harvesting period and extracts were prepared. The antidiabetic activities of the extracts were then analyzed using an α-glucosidase inhibitory assay.

Materials and methods

Reagents

α-glucosidase type 1 from baker's yeast (G5003; Sigma-Aldrich, St. Louis, MO, USA), p-nitrophenyl α-D-glucopyranoside (N1377, Sigma-Aldrich), sodium phosphate monobasic (S3139, Sigma-Aldrich), sodium phosphate dibasic (S5136, Sigma-Aldrich), filter paper (no. 1; Whatman Schleicher & Schuell, Keene, NH, USA), xanthone (95502; Fluka, Buchs St. Gallen, Switzerland) and acarbose (A8980, Sigma-Aldrich) were purchased for the purposes of this study.

Preparation of test material

The CT samples were obtained in Hampyeong, Korea, where the plants are collected on a monthly basis throughout the year. The plants were separated into leaves, roots and stems prior to being further subdivided into groups according to harvesting time. The samples underwent aqueous extraction for 2.5 h, were filtered with filter paper and lyophilized with a freeze dryer (IlShin Biobase Co., Ltd., Dongducheon, Korea). The lyophilized samples were dissolved in distilled water as 100 mg/ml stock and diluted with distilled water prior to the experiment. Nine CT samples were prepared: stems from plants harvested between late April and early May, 2009 (CT 1); stems harvested in middle June (CT 2); stems harvested between late July and early August (CT 3); stems harvested in middle September (CT 4); stems harvested in middle January (CT 5); roots and stems harvested in middle January (CT 6); leaves harvested in middle June (CT 7); leaves harvested between late July and early August (CT 8); and leaves harvested in middle September (CT 9).

Concentration of α-glucosidase and substrate

Sodium phosphate buffer (0.1 M) was adjusted by 0.1 N HCl to pH 7.0 with a pH meter (Thermo Fisher Scientific Inc., Waltham, MA, USA). p-Nitrophenyl α-D-glucopyranoside (10 mM) and α-glucosidase solutions (1 U/ml) were solubilized in 0.1 M sodium phosphate buffer (pH 7.0). All the reagents were manufactured shortly before use and warmed to 37°C in a water bath.

α-glucosidase inhibition assay

Sodium phosphate buffer (0.1 M, 158 μl per well) was added to a 96-well plate. α-Glucosidase (20 μl) and 2 μl of sample were added to 20 μl of p-nitrophenyl α-D-glucopyranoside. In the 200-μl final reaction volume (0.02 U/well, 0.1 U/ml) the substrate concentration was adjusted to 10 mM. The background signal due to the sample color was measured at 405 nm with the PerkinElmer Wallac Victor3 spectrophotometer (PerkinElmer, Waltham, MA, USA) prior to adding the enzyme. Immediately following α-glucosidase addition, absorbance was measured at 405 nm 8 times at 1-min intervals (10,11).

Creation of Lineweaver-Burk and Dixon plots

To predict whether the extracts contained similar patterns of compositions, a Lineweaver-Burk plot was created according to the Michaelis-Menten equation (12) together with a Dixon plot. This was performed instead of purifying, isolating and analyzing the active compounds by high-pressure liquid chromatography or thin layer chromatography. The protocol for obtaining data to create the Lineweaver-Burk plot was identical to that used for the α-glucosidase inhibitory assay. The α-glucosidase concentration was 0.1 U/ml, whereas the substrate was added at three concentrations: 0.1, 0.3, and 1.0 mM. The mode of inhibition was defined as competitive, non-competitive or mixed-type non-competitive, according to the Michaelis-Menten constants and the maximum velocity on the Lineweaver-Burk plot (13).

Results and Discussion

In the course of screening active antidiabetic agents, several medicinal plants were selected. The ability of CT extracts derived from nine different plant parts to inhibite α-glucosidase activity was investigated. As shown in Fig. 1, CT 1, CT 3 and CT 6 exhibited a significant inhibitory activity in a concentration-dependent manner. A kinetic study was performed to assess the effects of climate on the antidiabetic activity of the plant components, since functional food manufacturers are interested in identifying the active component concentrations during the growth of the leaves, stem and bark of the CT plant. To compare the inhibitory activities of the samples, acarbose was selected as positive control. With 1 mM of acarbose, the enzymatic velocity was decreased by ∼67% (Fig. 1). Similar to acarbose, almost all the extracts were associated with the same pattern of enzymatic velocity decrement, which was concentration-dependent. The most effective sample was demonstrated to be CT 6 (derived from the root of plants collected in middle January). Specifically, 300 μg/ml of this sample inhibited the enzymatic velocity by 77% (Fig. 2). By contrast, leaf extracts (300 μg/ml) exhibited marginal to no inhibition of the enzymatic activity (22% for CT 7, 8% for CT 8 and 0% for CT 9; Fig. 2). In a recent study (12), the majority of xanthone derivatives were reported to have activities similar to that of α-glucosidase. However, it was observed that xanthone, an organic compound with the molecular formula C13H8O2 that does not form derivatives, did not exert any obvious effect on α-glucosidase activity (data not shown).

Figure 1.

Comparison of α-glucosidase inhibition of the extracts according to harvesting time. Activities of the Cudrania tricuspidata (CT) extracts were measured according to the average increases of optical density. Data were calculated compared to the untreated sample and the experiment was performed in triplicate.

Figure 2.

Comparison of α-glucosidase inhibition according to a Lineweaver-Burk plot. Plots were generated based on the Michaelis-Menten equation. (A) Cudrania tricuspidata (CT) 1, (B) CT 3, (C) CT 4, (D) CT 5, (E) CT 6, (F) acarbose. Concentrations of A–E (μg/ml): ■, 300; △, 100; □, 30; ◆, 0. Concentrations of acarbose (mM): ◊, 3; ■, 0.1; △, 0.3; □, 0.1; ◆, 0.

The type of bioactive compounds present in the CT extracts and the composition changes in association with plant growth through the year were then determined. Five samples were selected and a Lineweaver-Burk plot was created based on the reciprocals of four different concentrations and the corresponding enzymatic velocities. As shown in Fig. 2, enzyme activities were reduced by the CT extracts in a dose-dependent manner and increased with substrate in a concentration-dependent manner. According to the Michaelis-Menten equation (1), the samples were classified according to the inhibition mode. The results were as follows (Fig. 3): CT 1, CT 4 and CT 6 as non-competitive inhibitors, CT 3 and CT 5 as competitive inhibitors and acarbose as a mixed-type non-competitive inhibitor. Our findings demonstrated that the stem extracts acted as non-competitive inhibitors, although one of them (CT 5) was classified as a competitive inhibitor. CT 6 exhibited the highest level of activity and was found to be a non-competitive inhibitor. Although the present data are not real activity values of CT, this approach is unique in assessing whether the extracts possess antidiabetic properties.

Figure 3.

Comparison of α-glucosidase inhibition using a Dixon plot. The results are shown in the Dixon plot (Fig. 2). (A) Cudrania tricuspidata (CT) 1, (B) CT 3, (C) CT 4, (D) CT 5, (E) CT 6, (F) acarbose. Concentration of substrate (mM): ◆, 0.125; □, 0.25; △, 0.5; ■, 1.

To analyze the mechanism underlying α-glucosidase inhibition, the inhibitor constant Ki was determined with a Dixon plot (Fig. 3). Based on the Michaelis-Menten equation, the Michaelis constant Km value also was calculated. The inhibitory types were identified based on the Lineweaver-Burk plot. Inhibitor constants were represented by intersections of the lines as substrate condition on the Dixon plot (13). As shown in Table I, competitive inhibitors had only one Vmax value whereas non-competitive inhibitors had one Km value. The inhibitor constant of CT 6, the most effective inhibitor, was 41.6 μg/ml. The inhibitor constant of acarbose was 0.22 μM. A previous study by Seo et al (2) reported that xanthone derivatives isolated from CT exhibit potent α-glucosidase inhibitory activity. Hwang et al (9) also obtained xanthone derivatives from the root bark of CT. Those studies suggested that the potent inhibitory effect of the CT root is attributed to the abundant levels of xanthone derivatives. Acarbose was also reported to be a competitive inhibitor of α-glucosidase activity (3,14). However, the results of the present study demonstrated that acarbose acted as a mixed-type non-competitive inhibitor.

Table I.

Determination of inhibitor constants for the Cudrania tricuspidata (CT) extracts.

Table I.

Determination of inhibitor constants for the Cudrania tricuspidata (CT) extracts.

Materials testedKm (mM)Km′ (mM)VmaxVmax′Ki
CT 10.431-0.08050.0518125.4±2.1
CT 30.4890.8840.0898-115.1±1.1
CT 40.376-0.05750.0416221.3±4.7
CT 50.5480.5880.0716-1,694.1±12.5
CT 60.417-0.07170.025841.6±0.5
Acarbose0.4160.4010.07160.1271220.0±7.0

[i] The inhibitor units were μg/ml for CT and mM for acarbose. Km, Michaelis constant without inhibitor; Km′, Michaelis constant with 100 μg/ml CT extracts or 0.3 mM acarbose; Vmax, maximum velocity of enzymatic activity without inhibitor; Vmax′, maximum velocity of enzymatic activity with 100 μg/ml CT extracts or 0.3 mM acarbose; Ki, inhibitory constants calculated with formulas derived from the Dixon plot analysis. Standard deviations for the Ki value were determined based on the intersection of the trend lines in the Dixon plot. Data were obtained from experiments performed in triplicate.

There were no differences observed in the inhibitory activities of CT 1–4 or CT 7–9 according to harvesting time. However, both stem and root extracts exerted potent inhibitory effects on α-glucosidase activity. Xanthone derivatives were previously isolated from the methanol fraction of the CT root and were demonstrated to inhibit α-glucosidase (2). In the present study, the aqueous fractions of the stem or root extracts were also found to possess potential inhibitory activities (data not shown). Our findings indicated that these fractions contain other compounds that are effective against α-glucosidase. In addition, the distribution of these compounds varied according to plant components and harvesting time. A previous study by Sen and Mukherji (15) reported that the carotenoid content of tomatoes undergoes seasonal variation. The results of their investigation demonstrated that carotenoid contents are highest in the winter and lowest during the rainy season. Therefore, it was hypothesized that CT 2, CT 8 and CT 9, which exhibited the lowest inhibitory activities among the stem and leaf samples, were affected by climatic conditions (Fig. 1). Since CT extract production in Korea is currently indiscriminate and in need of certification, our results may help define optimum conditions for the production of CT-containing foods or health beverages for antidiabetic purposes.

References

1 

Li YQ, Zhou FC, Gao F, Bian JS and Shan F: Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. J Agric Food Chem. 57:11463–11468. 2009. View Article : Google Scholar : PubMed/NCBI

2 

Seo EJ, Curtis-Long MJ, Lee BW, Kim HY, Ryu YB, Jeong TS, Lee WS and Park KH: Xanthones from Cudrania tricuspidata displaying potent alpha-glucosidase inhibition. Bioorg Med Chem Lett. 17:6421–6424. 2007.PubMed/NCBI

3 

Osonoi T, Saito M, Mochizuki K, Fukaya N, Muramatsu T, Inoue S, Fuchigami M and Goda T: The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism. 59:1816–1822. 2010.

4 

Lee BW, Lee JH, Gal SW, Moon YH and Park KH: Selective ABTS radical-scavenging activity of prenylated flavonoids form Cudrania tricuspidata. Biosci Biotechnol Biochem. 70:427–432. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Guan Y, Yin Z, Guo L, Huang X, Ye W and Shen W: Studies on chemical constituents from stems of Cudrania tricuspidata. Zhongguo Zhong Yao Za Zhi. 34:1108–1110. 2009.(In Chinese).

6 

Lee HJ, Do JR, Kwon JH and Kim HK: Physiological activities of extracts from different parts of Cudrania tricuspidata. J Korean Soc Food Sci Nutr. 40:942–948. 2011. View Article : Google Scholar

7 

Cha JY and Cho YS: Antioxidative activity of extracts from fruit of Cudrania tricuspidata. J Korean Soc Food Sci Nutr. 30:547–551. 2001.

8 

Chang SH, Jung EJ, Lim DG, Oyungerel B, Lim KI, Her E, Choi WS, Jun MH, Choi KD, Han DJ and Kim SC: Anti-inflammatory action of Cudrania tricuspidata on spleen cell and T lymphocyte proliferation. J Pharm Pharmacol. 60:1221–1226. 2008.

9 

Hwang JH, Hong SS, Han XH, Hwang JS, Lee D, Lee H, Yun YP, Kim Y, Ro JS and Hwang BY: Prenylated xanthones from the root bark of Cudrania tricuspidata. J Nat Prod. 70:1207–1209. 2007. View Article : Google Scholar : PubMed/NCBI

10 

Choi CW, Choi YH, Cha MR, Yoo DS, Kim YS, Yon GH, Hong KS, Kim YH and Ryu SY: Yeast α-glucosidase inhibition by isoflavones from plants of Leguminosae as an in vitro alternative to acarbose. J Agric Food Chem. 58:9988–9993. 2010.

11 

Nishio T, Hakamata W, Kimura A, Chiba S, Takatsuki A, Kawachi R and Oku T: Glycon specificity profiling of alpha-glucosidases using monodeoxy and mono-O-methyl derivatives of p-nitrophenyl alpha-D-glucopyranoside. Carbohydr Res. 124:629–634. 2002. View Article : Google Scholar

12 

Li GL, He JY, Zhang A, Wan Y, Wang B and Chen WH: Toward potent α-glucosidase inhibitors based on xanthones: a closer look into the structure-activity correlations. Eur J Med Chem. 46:4050–4055. 2011.

13 

Dixon M: The determination of enzyme inhibitor constants. Biochem J. 55:170–171. 1953.

14 

Kim MJ, Lee SB, Lee HS, Lee SY, Baek JS, Kim D, Moon TW, Robyt JF and Park KH: Comparative study of the inhibition of alpha-glucosidase, alpha-amylase, and cyclomaltodextrin glucanosyltransferase by acarbose, isoacarbose, and acarviosine-glucose. Arch Biochem Biophys. 371:277–283. 1999. View Article : Google Scholar

15 

Sen S and Mukherji S: Season-controlled changes in biochemical constituents and oxidase enzyme activities in tomato (Lycopersicon esculentum Mill.). J Environ Biol. 30:479–483. 2009.PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Son HU and Lee SH: Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time. Biomed Rep 1: 624-628, 2013.
APA
Son, H., & Lee, S. (2013). Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time. Biomedical Reports, 1, 624-628. https://doi.org/10.3892/br.2013.111
MLA
Son, H., Lee, S."Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time". Biomedical Reports 1.4 (2013): 624-628.
Chicago
Son, H., Lee, S."Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time". Biomedical Reports 1, no. 4 (2013): 624-628. https://doi.org/10.3892/br.2013.111
Copy and paste a formatted citation
x
Spandidos Publications style
Son HU and Lee SH: Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time. Biomed Rep 1: 624-628, 2013.
APA
Son, H., & Lee, S. (2013). Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time. Biomedical Reports, 1, 624-628. https://doi.org/10.3892/br.2013.111
MLA
Son, H., Lee, S."Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time". Biomedical Reports 1.4 (2013): 624-628.
Chicago
Son, H., Lee, S."Comparison of α‑glucosidase inhibition by Cudrania tricuspidata according to harvesting time". Biomedical Reports 1, no. 4 (2013): 624-628. https://doi.org/10.3892/br.2013.111
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team